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Tumoral calcinosis is a rare complication in uremic patients. An in-depth review of
published literature suggests that most patients with uremic tumoral calcinosis do
not respond to medical treatment. Here, we report the case of a patient on peritoneal
dialysis who presented with infected multifocal masses on both hip joints and was
successfully treated by medical intervention. The patient was diagnosed with uremic
tumoral calcinosis by physical examination and radiologic imaging, and treated with
low-calcium dialysis and a non-calcium phosphate binder, sevelamer, without
increasing the dose of dialysis. At the 36-month follow-up, the majority of masses
had disappeared and the patient was asymptomatic.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tumoral calcinosis is a rare condition characterized by
calcium phosphate deposits in subcutaneous soft tissues
usually around the joints. The prevalence of uremic tumoral
calcinosis in patients undergoing peritoneal dialysis (PD) was
estimated by a Japanese study [1] to be 1.6%, roughly equiva-
lent to its prevalence in hemodialysis patients. Although the
pathogenesis of uremic tumoral calcinosis is not yet fully
understood, it is commonly associated with a buildup of
calcium-phosphate product and hyperparathyroidism.
Here, we present the case of a patient on PD in whom severe
tumoral calcinosis with infection developed. Near-complete reso-
lution of deposits was achieved following administration of
antibiotics, low-calcium dialysate, and sevelamer treatment.
Case report
A 25-year-old man treated with PD for 49 years presented
with painful masses on both buttocks and hip joints. The patientn Society of Nephrology. Publi
c-nd/4.0/).
nal Medicine, Keimyung
Junggu, Daegu, Korea.
g).had end-stage renal disease secondary to Schönlein–Henoch
purpura, and underwent a kidney transplant 16 years previously.
Following gradual deterioration of allograft function, PD had been
initiated 7 years after transplantation. The PD schedule comprised
four exchanges of 1.5 L dialysate (Perisis, Boryung, Korea) with
3.5 mEq/L calcium. A calcium acetate phosphate binder (2,130 mg)
had been added during the past 5 years of PD, and active vitamin
D3 was administered intermittently. The patient was anuric with
weekly Kt/V urea values of 1.633.
On admission, physical examination revealed painful nodular
masses around both hip joints and buttocks. Themasses were ﬁrm
and lobular with signs of soft-tissue infection. Laboratory ﬁndings
were as follows: hemoglobin, 7.5 g/dL; total calcium, 9.9 mg/dL;
phosphate, 3.7 mg/dL; intact parathyroid hormone (iPTH),
417.6 pg/mL; and C-reactive protein (CRP), 31.2 mg/dL. Micro-
biologic blood culture results were positive for Staphylococcus
haemolyticus. Pelvic radiography revealed tumoral calcinosis in
both hip joints (Fig. 1). A technetium 99m scan showed increased
uptake in both hip joints and shoulders (Fig. 2A).
First-generation cephalosporin was administered, and calcium
acetate was replaced with sevelamer, a non-calcium containing
phosphate binder. After 1 month, the serum calcium and ionized
calcium levels were 10.7 mg/dL and 2.56 mEq/L, respectively. PD
ﬂuid was switched to low-calcium dialysate (2.5 mEq/L calcium).shed by Elsevier. This is an open access article under the CC BY-NC-ND
Figure 1. Radiographic images of the patient's pelvis. (A) Massive calcium deposition is evident around both hip joints at the time of admission.
(B) Minimal calcium deposition has revealed after 36 months of treatment.
Figure 2. Technetium 99m bone scans of the patient. (A) Tumoral calcinosis is evident in the left hip joint and both shoulders at the time of
admission. (B) Tumoral calcinosis has resolved after 36 months of treatment.
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Figure 3. Changes in total calcium, phosphorus, and iPTH according
to treatment with low calcium dialysate and sevelamer. adm,
admission; Vit D3, calcitriol; T-Ca, total calcium; PO4, phosphorus.
Kim et al / Uremic tumoral calcinosis in PD 227After 12months, the patient was symptom free and serum calcium
levels reduced to 8.8 mg/dL. After 17months, the patient remained
asymptomatic, although serum calcium levels were reduced to
8.5 mg/dL, and iPTH levels were increased to 734.1 pg/mL. Active
vitamin D3 was readministered. Over the following 12 months,
serum calcium level remained between 9.2 mg/dL and 10mg/dL,
phosphate level between 4.0 mg/dL and 6.0 mg/dL, and iPTH level
o350 pg/mL. By 36 months, a follow-up bone scan conﬁrmed
striking resolution of tumoral calcinosis, with only a small residual
lesion near the left femoral head (Fig. 2B).
Currently, the patient is asymptomatic, with serum calcium
level of 9.3 mg/dL, serum phosphate level of 5.6 mg/dL, and
serum iPTH level of 226 pg/mL (Fig. 3).
Discussion
We presented a case of uremic tumoral calcinosis in a
patient undergoing PD with moderate hyperparathyroidism.
Kidney Res Clin Pract 33 (2014) 226–228228In this study, PD was not substituted for, or combined with,
hemodialysis. Treatment of tumoral calcinosis, comprising
administration of low-calcium dialysate with a non-calcium-
containing phosphate binder, resulted in near-complete reso-
lution of pathology.
Uremic tumoral calcinosis is a rare complication in uremic
patients. Its etiology is incompletely understood, although
increased deposition of calcium-phosphate product secondary
to hyperparathyroidism, dialysis vintage, and vitamin D intoxi-
cation have been implicated in its pathogenesis [2]. In the
patient described here, iPTH level increased to 417.6 pg/mL
without an increase in the calcium-phosphate product level
beyond 36.6 mg2/dL2, contrary to previous reports by Chu et al
[1], in which all of seven cases of uremic tumoral calcinosis
were associated high calcium-phosphate product levels. In this
instance, however, the dialysis vintage of 49 years was longer
than that previously reported.
Uremic tumoral calcinosis can be unifocal or multifocal, and
patients may present with localized swelling, pain, pruritus,
ulceration, and infection [3]. Lesions are typically observed
around the weight-bearing joints particularly susceptible to
excessive wear, such as the shoulders, elbows, and hips. In this
case, the predominant manifestation was painful multifocal
masses on both hip joints, although a bone scan revealed
additional lesions in the patient’s shoulders. Upon physical
examination, signs of infection were observed around the
masses. Hamada et al [3] previously reported that 25% of
patients with uremic tumoral calcinosis present with infection.
Several medical and surgical strategies have been consid-
ered for the treatment of uremic tumoral calcinosis. Medical
treatment consists of a non-calcium phosphate binder, low-
calcium dialysate, or increased dose of dialysis. A thorough
literature review identiﬁed 16 published cases of PD patients
with uremic tumoral calcinosis. In all cases, medical treatment
was unsuccessful [1]. Chu et al [1] reported that two of seven
patients received only medical therapy including a phosphate-
restricted diet, a calcium or non-calcium phosphate binder,
and intensive dialysis with low-calcium dialysate (2 mEq/L).
However, medical therapy was ineffective in all cases. In cases
of hemodialysis patients with uremic tumoral calcinosis, daily
hemodialysis with a low-calcium dialysate or daily nocturnaldialysis has been found to effectively decrease and resolve
massive tumoral calcinosis [4,5].
Kuriyama et al [6] suggested that combining hemodialysis
with PD using a low-calcium dialysate can be effective in
patients undergoing PD with tumoral calcinosis. Surgical
treatment, including excision of calciﬁc masses or parathyr-
oidectomy in case of severe secondary hyperparathyroidism, is
indicated in patients resistant to medical treatment. It is
interesting that in the case presented here, near-complete
resolution of uremic tumoral calcinosis was observed after 36
months of medical intervention with low-calcium dialysis and
sevelamer, a non-calcium phosphate binder.
In conclusion, medical management with low-calcium
dialysate and a non-calcium phosphate binder over a pro-
longed interval can resolve massive uremic tumoral calcinosis
in patients with PD.Conﬂict of interest
All authors declare no conﬂict of interest.
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